AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca’s ovarian cancer drug Lynparza is facing competition in Europe with Tesaro's rival Zejula now set for launch. Zejula (niraparib) has now gained final marketing approval from the the ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

PE: The six-year follow-up from the OlympiA trial showed a 28% reduction in the risk of death with Lynparza. How does this result compare to other treatments available for gBRCAm HER2-negative ...

Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, Lynparza and Symbicort, beating estimates. The British drugmaker said that the ...